Literature DB >> 2533247

Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.

S M Crowe1, M S McGrath, T Elbeik, J Kirihara, J Mills.   

Abstract

We compared the efficacy of 3 antiretrovirals in cultured human peripheral blood monocyte-derived macrophages and lymphoid cells infected with the human immunodeficiency virus (HIV). Zidovudine (greater than 0.01 micrograms/ml) or foscarnet (greater than or equal to 100 micrograms/ml) consistently inhibited HIV replication (p24 antigen production) in acutely infected macrophages by more than 90%; alpha interferon (1,000 units/ml) inhibited HIV replication by 88-99%. Drug efficacy was equal in lymphoid cells and monocyte-derived macrophages. However, these antiretrovirals even in high concentration only minimally inhibited chronic, established HIV infection: while zidovudine (0.01 micrograms/ml) inhibited infection by over 90% in acutely infected macrophages and lymphoid cells, 50 micrograms/ml of this antiretroviral produced only 19-55% inhibition of HIV replication in chronically infected cells. Slot-blot analysis of HIV RNA was concordant with the p24 antigen data. Acutely infected macrophages are as susceptible to the inhibitory effects of antiretrovirals as lymphoid cells; however, chronically infected macrophages (which probably constitute the main in vivo reservoir for HIV) are several orders of magnitude more resistant.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533247     DOI: 10.1002/jmv.1890290306

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

2.  Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex.

Authors:  J O Kahn; K J Gorelick; G Gatti; C J Arri; J D Lifson; J G Gambertoglio; A Bostrom; R Williams
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy.

Authors:  Janice E Clements; Ming Li; Lucio Gama; Brandon Bullock; Lucy M Carruth; Joseph L Mankowski; M Christine Zink
Journal:  J Neurovirol       Date:  2005-04       Impact factor: 2.643

Review 4.  HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments.

Authors:  Adonira Saro; Zhaolin Gao; Piniel Alphayo Kambey; Paul Pielnaa; Dama Faniriantsoa Henrio Marcellin; Aixiang Luo; Ruping Zheng; Zhongjun Huang; Lvshuang Liao; Mingxuan Zhao; Liangpeng Suo; Shuang Lu; Min Li; Deyang Cai; Dan Chen; Haiyang Yu; Jufang Huang
Journal:  Cell Mol Neurobiol       Date:  2021-09-25       Impact factor: 4.231

5.  Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.

Authors:  T Igarashi; C R Brown; Y Endo; A Buckler-White; R Plishka; N Bischofberger; V Hirsch; M A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 6.  Novel Nanotechnology-Based Approaches for Targeting HIV Reservoirs.

Authors:  Leila Fotooh Abadi; Fouad Damiri; Mehrukh Zehravi; Rohit Joshi; Rohan Pai; Mohammed Berrada; Ehab El Sayed Massoud; Md Habibur Rahman; Satish Rojekar; Simona Cavalu
Journal:  Polymers (Basel)       Date:  2022-07-29       Impact factor: 4.967

7.  Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis.

Authors:  Jessica Young; Zhongwei Tang; Quan Yu; Dongyang Yu; Yuntao Wu
Journal:  Retrovirology       Date:  2008-04-25       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.